AZITHROMYCIN SUPPRESSES HUMAN OSTEOCLAST FORMATION AND ACTIVITY IN VITRO

A thesis submitted to the University of Adelaide in partial fulfilment of the requirements of the Degree of Doctor of Clinical Dentistry (Periodontology)

Siobhan Catherine Gannon BDSc (Hons) (UQ)
# Table of Contents

Abstract.................................................................................................................. v

Declaration............................................................................................................... vi

Statement of Authorship ....................................................................................... vii

Acknowledgements ............................................................................................... ix

Chapter 1. Literature review of the pathogenesis of bone loss in periodontitis and the use of azithromycin in periodontal treatment.......................................................................... 1

1.1 Introduction.................................................................................................. 1

1.2 Bone Resorption in Periodontitis ............................................................. 1

1.3 Osteoclast Formation and Activation ....................................................... 2

1.4 Regulation of Bone Resorption ................................................................. 3

1.4.1 RANKL/RANK ......................................................................................... 3

1.4.2 Osteoprotegerin (OPG) ........................................................................... 4

1.4.3 Macrophage colony-stimulating factor .................................................... 4

1.4.4 Osteoclast Intracellular Signalling .......................................................... 4

1.4.4.1 TNF receptor associated factors.............................................................. 5

1.4.4.2 Nuclear factor kappa light chain enhancer of activated B cells .............. 5

1.4.4.3 Activator protein-1 .................................................................................. 5

1.4.4.4 Nuclear factor of activated T cells ........................................................... 5

1.5 The Host Response and Bone Resorption in Periodontitis ...................... 6

1.5.1 RANKL and OPG in Periodontitis ............................................................ 7

1.5.2 Summary.................................................................................................. 9

1.6 The Use of Antibiotics in Periodontal Treatment ....................................... 9

1.6.1 What is Azithromycin? ............................................................................ 10

1.6.1.1 Structure ................................................................................................ 10

1.6.2 Uses ....................................................................................................... 11

1.6.3 Pharmacokinetic and Pharmacodynamic Properties .......................... 11

1.6.4 Safety and Adverse Effects ................................................................... 13

1.7 Antimicrobial Properties of Azithromycin .............................................. 14

1.7.1 Activity Against Periodontal Pathogens ................................................. 14

1.7.2 Effect on Biofilms .................................................................................... 15

1.7.3 Antibiotic Resistance ............................................................................. 16

1.8 Immunomodulatory Properties ................................................................. 17

1.8.1 Effects on Cytokine Production and Transcription Factor Expression .... 17

1.8.2 Effects on Innate Immune Cells .............................................................. 19
1.8.2.1 Polymorphonuclear leukocytes ................................................................. 20
1.8.2.2 Monocytes ............................................................................................... 21
1.8.2.3 Macrophages ............................................................................................ 21
1.8.2.4 Dendritic Cells ......................................................................................... 22
1.8.2.5 Other Cell Types ..................................................................................... 23

1.8.3 Effects on Adaptive Immunity ...................................................................... 23
1.8.4 Effects on Osteoclasts .................................................................................. 23
1.8.5 Effects in the Periodontal Tissues .................................................................. 24

1.9 Therapeutic Use in Periodontal Treatment ...................................................... 24

1.9.1 Microbiological Effects of Azithromycin in Periodontal Treatment .......... 25
1.9.1.1 Chronic Periodontitis .................................................................................. 25
1.9.1.2 Aggressive Periodontitis ............................................................................ 26
1.9.2 Bacteraemia During Periodontal Treatment .................................................. 26
1.9.3 Clinical Effects in the Nonsurgical Treatment of Chronic Periodontitis .... 26
1.9.3.1 Systemic Azithromycin .............................................................................. 26
1.9.3.2 Locally Delivered Azithromycin ................................................................. 29
1.9.4 Clinical Effects in the Nonsurgical Treatment of Aggressive Periodontitis 29
1.9.5 Treatment of Periodontal Abscesses .............................................................. 29
1.9.6 Periodontal Surgery ...................................................................................... 30
1.9.7 Peri-implant Mucositis ................................................................................. 30
1.9.8 Treatment of Gingival Enlargement .............................................................. 30
1.9.8.1 Mechanisms ............................................................................................... 32

1.10 Conclusion ....................................................................................................... 32
1.10.1 Study Rationale, Hypothesis and Aims ...................................................... 33

1.11 References ....................................................................................................... 34

Chapter 2. Azithromycin suppresses human osteoclast formation and activity in vitro. 58

Conflict of Interest and Source of Funding Statement ............................................. 58

The authors of this study have no conflicts of interest to declare. .......................... 58
This study was supported by grants from the National Health and Medical Research Council of Australia (Project Grant 565341) and the Australian Dental Research Foundation (Project Grant 70/2011) ........................................ 58

2.1 Introduction .......................................................................................................... 59

2.2 Materials and Methods ..................................................................................... 60
2.2.1 Cell Culture .................................................................................................. 60
2.2.2 Azithromycin Treatment ............................................................................. 61
2.2.3 WST-1 Cell Viability Assay ......................................................................... 61
**Table of Figures**

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Structure of Azithromycin (Image from (Culic et al., 2001))</td>
<td>11</td>
</tr>
<tr>
<td>2.1</td>
<td>Effect of azithromycin on osteoclast differentiation and resorptive ability</td>
<td>80</td>
</tr>
<tr>
<td>2.2</td>
<td>Effect of azithromycin on osteoclast formation and activity</td>
<td>81</td>
</tr>
<tr>
<td>2.3</td>
<td>Effect of azithromycin on osteoclast morphology and nuclei number</td>
<td>82</td>
</tr>
<tr>
<td>2.4</td>
<td>Azithromycin inhibits actin ring formation but does not affect osteoclast V-</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>ATPase activity</td>
<td></td>
</tr>
<tr>
<td>2.5</td>
<td>Fold changes in mRNA expression of key osteoclast genes with azithromycin</td>
<td>84</td>
</tr>
<tr>
<td></td>
<td>treatment</td>
<td></td>
</tr>
<tr>
<td>2.6</td>
<td>Differential effect of azithromycin on osteoclast gene expression depending</td>
<td>85</td>
</tr>
<tr>
<td></td>
<td>on culture substrate</td>
<td></td>
</tr>
<tr>
<td>2.7</td>
<td>NFATc1 staining</td>
<td>86</td>
</tr>
</tbody>
</table>
Abstract

Azithromycin is an antibiotic with anti-inflammatory properties used as an adjunct in the treatment of periodontitis, a common inflammatory mediated condition featuring pathologic alveolar bone resorption. The aim of this study was to determine the effect of azithromycin on human osteoclast formation and resorptive activity in vitro. Osteoclasts were generated from peripheral blood mononuclear cells stimulated with macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B (RANK) ligand. The effects of azithromycin at concentrations ranging from 0.5 µg/mL to 40 µg/mL were tested. Osteoclast formation and activity, acidification, actin ring formation and expression of mRNA and protein encoding for key osteoclast genes were assessed. The results demonstrated that azithromycin reduced osteoclast resorptive activity at all concentrations tested with osteoclast formation being significantly reduced at the higher concentrations (20µg/mL and 40µg/mL). mRNA and protein expression of the key osteoclast transcription factor Nuclear Factor of Activated T cells (NFATc1) was significantly reduced by azithromycin at later stages of osteoclast development (day 17). Azithromycin also reduced tumour necrosis factor receptor associated factor-6 (TRAF6) mRNA expression at day 14, and cathepsin K mRNA expression at day 14 and 17. Integrin β3 and MMP-9 mRNA expression was reduced by azithromycin at day 17 in osteoclasts cultured on dentine. The osteoclast proton pump did not appear to be affected by azithromycin, however formation of the actin ring cytoskeleton was inhibited. This study demonstrates that azithromycin inhibits human osteoclast function in vitro, which may account for at least some of the beneficial clinical effects observed with azithromycin treatment in periodontitis.
Declaration

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution to Siobhan Catherine Gannon and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis (as listed below) resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue, and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Published Works:

Declared by: Dr Siobhan Gannon Witnessed by:
Signature: Date:
Statement of Authorship

NOTE: The Statement of authorship appears in the print copy of the thesis held in the University of Adelaide Library.
Acknowledgements

This study was supported by grants from the Australian Dental Research Foundation and the National Health and Medical Research Council of Australia.

I would like to acknowledge my principal research supervisor Professor Mark Bartold for inception of the research topic, as well as for guidance and feedback throughout the duration of my Doctor of Clinical Dentistry candidature. I would also like to thank Dr Bryon Kardachi and Dr Robert Hirsch for imparting their knowledge and clinical skills as research supervisors and teachers throughout the last 3 years.

I am indebted to Melissa Cantley for her invaluable help in designing the research project, as well as instruction in and supervision of laboratory work. Her expertise, input, enthusiasm and support were instrumental in the completion of this research project. I would also like to thank Associate Professor David Haynes for advice and guidance, and for making available the use of his laboratory.

Thankyou to Mr Dale Caville who provided assistance with microphotography and Ms Lynnette Waterhouse of Adelaide Microscopy who provided guidance and instruction in the use of confocal and scanning electron microscopy.

I would also like to thank Catherine Offler from the Colgate Australian Clinical Dental Research Centre for her assistance in the final editing of the manuscript.